Krishna Jayaraman Ph.D., CEO & Co-Founder. Led GMSbiotech as the President & CEO since its inception. He has 25 years of senior management experience in diagnostic and therapeutic industry including Kodak & Motorola and small biotech companies including Gemini Biotech where he was the founder & CEO. Gemini biotech was acquired by a small public company where he became the Vice Chairman of the Board. He has held Board & Advisory positions in several startup companies. He was a director of R& D at Motorola Biochip Systems and led technology evaluation for acquisitions and led a $30 million dollar R &D collaboration with Hoechst while he was at Triplex Pharmaceuticals. He has published over 45 papers in prestigious journals and has 6 awarded patents to his credit.
Michael Hogan Ph.D., Co-Founder, Chief Scientific Officer and Chairman, Scientific Advisory Board, is an expert in the microarray field. Prior to GMSbiotech, he has founded three companies that were funded by first-tier venture capital in oligonucleotide therapeutics, microarray and applied genomics arena. He has been Faculty at Princeton, Baylor College of Medicine and The University of Arizona. He has 19 awarded patents, 12 pending patents and 93 publications in biophysics, applied genetics & biotechnology.
Krystylle L. Richardson, BSIE, SSGB, RABQSA Auditor, Vice President of Quality Systems and Regulatory Affairs, is the owner of the G3QARA Group. With 20+ years of quality and regulatory management, engineering, auditing and consulting experience, she has partnered with companies to achieve medical device registration by preparing documentation and technical files for 510k’s, PMA’s and CE Marking of their products through compliance to 21CFR Part 820, MDD, IVDD, ISO 9001 and ISO 13485. Krystylle is a certified auditor, a member of the Regulatory Affairs Professional Society and a Six Sigma Green Belt. Krystylle has conducted training for personnel at all organizational levels, across numerous industries and in 13 countries in Process and Software Validation Master Planning and execution, risk management per ISO 14971, Six Sigma Philosophies and techniques, Cost of Quality, communicating with the FDA regarding 483 observation corrective and preventive actions as well as medical device and vigilance reporting.